Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
67%(6 trials)

Phase Distribution

Ph phase_2
3
33%
Ph phase_3
2
22%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 23 (33.3%)
Phase 32 (22.2%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

NCT02454972
completedphase_3

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

NCT02566993
completedphase_3

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

NCT02421588
completedphase_1

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

NCT01970540
completedphase_2

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

NCT02451007
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02454972Phase 2

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Completed
NCT02566993Phase 3

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Completed
NCT02421588Phase 3

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

Completed
NCT01970540Phase 1

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Completed
NCT02451007Phase 2

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Completed
NCT01951157Phase 2

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Completed
NCT01980667Phase 1

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Completed
NCT02210364Phase 1

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Completed
NCT01970553Phase 1

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9